SG11202002489YA - Anti-transthyretin antibodies - Google Patents
Anti-transthyretin antibodiesInfo
- Publication number
- SG11202002489YA SG11202002489YA SG11202002489YA SG11202002489YA SG11202002489YA SG 11202002489Y A SG11202002489Y A SG 11202002489YA SG 11202002489Y A SG11202002489Y A SG 11202002489YA SG 11202002489Y A SG11202002489Y A SG 11202002489YA SG 11202002489Y A SG11202002489Y A SG 11202002489YA
- Authority
- SG
- Singapore
- Prior art keywords
- transthyretin antibodies
- transthyretin
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762569436P | 2017-10-06 | 2017-10-06 | |
| US201762598965P | 2017-12-14 | 2017-12-14 | |
| PCT/US2018/054720 WO2019071205A1 (fr) | 2017-10-06 | 2018-10-05 | Anticorps anti-transthyrétine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002489YA true SG11202002489YA (en) | 2020-04-29 |
Family
ID=65994817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002489YA SG11202002489YA (en) | 2017-10-06 | 2018-10-05 | Anti-transthyretin antibodies |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11267877B2 (fr) |
| EP (1) | EP3691447A4 (fr) |
| JP (1) | JP7357609B2 (fr) |
| KR (1) | KR20200074956A (fr) |
| CN (1) | CN111315213B (fr) |
| AU (1) | AU2018345806A1 (fr) |
| BR (1) | BR112020006434A2 (fr) |
| CA (1) | CA3077361A1 (fr) |
| CU (1) | CU20200021A7 (fr) |
| MX (1) | MX2020003041A (fr) |
| PE (1) | PE20210552A1 (fr) |
| SA (1) | SA520411703B1 (fr) |
| SG (1) | SG11202002489YA (fr) |
| WO (1) | WO2019071205A1 (fr) |
| ZA (1) | ZA202002141B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| BR112020006434A2 (pt) | 2017-10-06 | 2020-11-03 | Prothena Biosciences Limited | anticorpos anti-transtirretina |
| WO2019108689A1 (fr) | 2017-11-29 | 2019-06-06 | Prothena Biosciences Limited | Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine |
| CN115551886A (zh) | 2020-05-12 | 2022-12-30 | 生物控股有限公司 | 用于ttr淀粉样变性的联合疗法 |
| WO2023099788A1 (fr) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Nouveau dosage de puissance pour des médicaments à base d'anticorps et moyens utiles associés |
| WO2023205739A2 (fr) * | 2022-04-20 | 2023-10-26 | Senti Biosciences, Inc. | Domaines de liaison à un antigène et leurs méthodes d'utilisation |
| WO2024121156A1 (fr) | 2022-12-05 | 2024-06-13 | Neurimmune Ag | Composés cycliques et leur utilisation dans des dosages pour détecter des anticorps |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| EP1353944A2 (fr) | 2000-04-05 | 2003-10-22 | The University Of Tennessee Research Corporation | Techniques d'etude, de diagnostic et de traitement d'amylose |
| WO2010012004A2 (fr) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Anticorps monoclonaux spécifiques d'agrégats amyloïdes pathologiques communs aux amyloïdes formés à partir de protéines ayant des séquences différentes |
| US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
| US9535076B2 (en) | 2002-09-12 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
| WO2004024090A2 (fr) | 2002-09-12 | 2004-03-25 | The Regents Of The University Of California | Immunogenes et anticorps correspondant specifiques pour des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides constitues par des proteines de sequences differentes |
| EP1660533A4 (fr) | 2003-09-12 | 2009-10-21 | Univ California | Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente |
| US8236933B2 (en) * | 2005-04-13 | 2012-08-07 | Garvan Institute Of Medical Research | Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor |
| EP2514823B1 (fr) | 2006-03-03 | 2018-05-02 | ProMIS Neurosciences Inc. | Procédés et compositions pour traiter et détecter des maladies à médiation par SOD1 à mauvais repliement |
| WO2008005455A2 (fr) * | 2006-07-03 | 2008-01-10 | The Johns Hopkins University | Déplétion des peptides par anticorps et son application à la préparation des échantillons pour spectrométrie de masse |
| EP2548647B1 (fr) | 2006-10-20 | 2018-08-15 | CLONDIAG GmbH | Dispositifs et méthodes de dosage destinés à la détection de substances á analyser |
| WO2010030203A1 (fr) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Anticorps monoclonal dirigé contre la transthyrétine humaine amyloïdogène et des formes modifiées de celle-ci et son utilisation dans la détection et le traitement de la fap et de pathologies présentant une ttr modifiée |
| US20100233176A1 (en) | 2008-10-06 | 2010-09-16 | Cashman Neil R | Methods and systems for predicting misfolded protein epitopes |
| JP2010195710A (ja) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| CA2753621A1 (fr) | 2009-03-02 | 2010-09-10 | The University Of British Columbia | Anticorps et epitopes specifiques d'une proteine prion dite tordue |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| FI20115165A0 (fi) | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| EP2679681B2 (fr) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps Fc spécifique de FcgammaRIIb |
| DK2698431T3 (da) | 2011-03-30 | 2020-11-30 | Chugai Pharmaceutical Co Ltd | Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| ES2856272T3 (es) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| JP2016514091A (ja) | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| DK2995680T3 (en) * | 2013-03-12 | 2018-12-17 | Univ Nagoya Nat Univ Corp | PROCEDURE FOR INCREASING PHOTOSYNTHESIS AND PLANTS OF PLANTS |
| US20160168235A1 (en) | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| DK3083681T3 (da) * | 2013-12-20 | 2020-08-24 | Neurimmune Holding Ag | Antistofbaseret terapi af transthyretin- (ttr) amyloidose og human-afledte antistoffer dertil |
| CN106459956B (zh) | 2014-01-29 | 2019-12-17 | 一般财团法人化学及血清疗法研究所 | 抗-运甲状腺素蛋白人抗体 |
| CN106574258B (zh) | 2014-01-29 | 2021-03-30 | Km生物医药股份公司 | 抗-运甲状腺素蛋白人源化抗体 |
| KR102631505B1 (ko) | 2014-08-29 | 2024-02-01 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법 |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI718121B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7076711B2 (ja) | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| WO2018007924A2 (fr) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anticorps anti-transthyrétine |
| MX2020003043A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Métodos para detectar transtiretina. |
| BR112020006434A2 (pt) | 2017-10-06 | 2020-11-03 | Prothena Biosciences Limited | anticorpos anti-transtirretina |
| WO2019108689A1 (fr) | 2017-11-29 | 2019-06-06 | Prothena Biosciences Limited | Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine |
| WO2021168156A1 (fr) | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Surveillance de l'amyloïdose de la transthyrétine |
-
2018
- 2018-10-05 BR BR112020006434-3A patent/BR112020006434A2/pt unknown
- 2018-10-05 EP EP18863984.3A patent/EP3691447A4/fr active Pending
- 2018-10-05 MX MX2020003041A patent/MX2020003041A/es unknown
- 2018-10-05 US US16/753,307 patent/US11267877B2/en active Active
- 2018-10-05 AU AU2018345806A patent/AU2018345806A1/en active Pending
- 2018-10-05 SG SG11202002489YA patent/SG11202002489YA/en unknown
- 2018-10-05 CU CU2020000021A patent/CU20200021A7/es unknown
- 2018-10-05 CN CN201880071788.1A patent/CN111315213B/zh active Active
- 2018-10-05 PE PE2020000481A patent/PE20210552A1/es unknown
- 2018-10-05 JP JP2020518649A patent/JP7357609B2/ja active Active
- 2018-10-05 KR KR1020207012722A patent/KR20200074956A/ko not_active Application Discontinuation
- 2018-10-05 CA CA3077361A patent/CA3077361A1/fr active Pending
- 2018-10-05 WO PCT/US2018/054720 patent/WO2019071205A1/fr active Application Filing
-
2020
- 2020-04-05 SA SA520411703A patent/SA520411703B1/ar unknown
- 2020-05-04 ZA ZA2020/02141A patent/ZA202002141B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200074956A (ko) | 2020-06-25 |
| SA520411703B1 (ar) | 2024-04-28 |
| CN111315213A (zh) | 2020-06-19 |
| PE20210552A1 (es) | 2021-03-17 |
| BR112020006434A2 (pt) | 2020-11-03 |
| WO2019071205A1 (fr) | 2019-04-11 |
| AU2018345806A1 (en) | 2020-03-12 |
| ZA202002141B (en) | 2023-01-25 |
| CA3077361A1 (fr) | 2019-04-11 |
| EP3691447A1 (fr) | 2020-08-12 |
| MX2020003041A (es) | 2020-10-05 |
| CN111315213B (zh) | 2023-09-12 |
| JP2020536532A (ja) | 2020-12-17 |
| JP7357609B2 (ja) | 2023-10-06 |
| US20200331992A1 (en) | 2020-10-22 |
| US11267877B2 (en) | 2022-03-08 |
| CU20200021A7 (es) | 2021-01-12 |
| EP3691447A4 (fr) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268517A (en) | Anti-tigit antibodies | |
| IL272227A (en) | ANTI-TIGIT antibodies | |
| ZA201905966B (en) | Anti-lag3 antibodies | |
| PL3625259T3 (pl) | Przeciwciała anty-sirpalfa | |
| IL267797B1 (en) | Anti-gpc3 antibody | |
| GB201709808D0 (en) | Antibodies | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| IL273393A (en) | New epsilon anti-CD3 antibodies | |
| SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
| ZA202002141B (en) | Anti-transthyretin antibodies | |
| GB201720970D0 (en) | Antibodies | |
| ZA202103456B (en) | Anti-alpha-synuclein antibodies | |
| IL271067A (en) | Anti-trkb antibodies | |
| IL273529A (en) | Anti-PACAP antibody | |
| RS62884B1 (sr) | Antitela protiv il-22r | |
| GB201711785D0 (en) | Antibodies | |
| GB201717006D0 (en) | Anti-OPG antibodies | |
| GB201709818D0 (en) | Antibodies | |
| GB201703071D0 (en) | Antibodies | |
| GB201701416D0 (en) | Anti-OPG antibodies | |
| GB201709592D0 (en) | Antibody |